Skip to content
Nutriband
  • Home
  • About
    • Management
    • Board of Directors
    • Advisory Board
    • Careers
    • Nutriband Costa Rica
    • Investors
  • Pipeline
  • Capabilities
  • News
  • Contact Us

ACR

By Paddy Ryan / October 26, 2022

Post navigation
← Previous Media

Recent Posts

  • Nutriband to Attend 2023 BIO International Convention
  • Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023
  • Nutriband Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023
  • Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Scale Manufacturing Process Development
  • Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology
Nutriband - Logo - Leaders in Transdermal Technology

Its our goal to improve patient comfort, safety and efficacy while setting new safety standards for notoriously abused, yet extremely effective medications!

Linkedin Twitter Facebook

Quick Links

  • Home
  • About Us
  • Our Pipeline
  • Capabilities
  • 4P Therapeutics
  • Pocono Pharma

Company Info

  • NTRB Filings
  • NTRB Stock Info
  • NTRB Investor Info
  • Management Team
  • Latest Press Releases
  • Privacy and Cookies Policy
  • NTRB and GDPR

Contact Info

Nutriband Pharma
121 S. Orange Ave.,
Suite 1500,
Orlando,
FL 32801
[email protected]

Copyright © 2023 Nutriband
Powered by Trigger Media